Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations
No Summary
Anika R. Sabnis
4 papers in the library · 3 citations · publishing 2025-2026
Papers
Novel 5,6-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches
ACS Medicinal Chemistry Letters June 3, 2026 Ram W. Sabnis, Anika R. Sabnis
This patent describes novel 5,6-bicyclic compounds that act as agonists of the 5-HT2A receptor. These compounds are intended for use in pharmaceutical compositions to treat conditions such as depression, anxiety, substance abuse, and headaches. The document also outlines processes for synthesizing these compounds. No experimental data, results, or clinical findings are presented.
Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett April 27, 2026 Ram W. Sabnis, Anika R. Sabnis
No Summary
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett February 13, 2025 Ram W. Sabnis, Anika R. Sabnis
The text describes novel tryptamine compounds that act as agonists at the 5-HT2A receptor, a serotonin receptor subtype, for potential treatment of mood disorders including depressive disorders and bipolar disorders. The work presents these compounds as a therapeutic approach, but no specific findings, experimental results, or clinical data are reported.